CAR-T Meeting 2023 | Investigating the co-occurrence of CRS and ICANS after CAR-T therapy & the need for novel therapies
Vibhu Agarwal, PhD, Medidata Solutions, Acorn AI, New York City, NY, discusses an analysis on the co-occurrence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients treated with CAR-T cell therapy. Although the pathways involved in CRS are well understood and have been extensively researched, Dr Agarwal explains that less is known about the mechanisms driving the development of ICANS. Results from this analysis demonstrated that pre-emptive treatment with rescue therapies does not reduce the incidence of ICANS, suggesting that novel therapies may be required. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
